Bernstein Research Analysts Shatters Boston Scientific (NYSE:BSX) Stock Rating to Market Perform – BSX, JNJ, ABT, ACAD, PFE, MYL, MRK, BMY, SRPT

Boston Scientific Corporation (NYSE:BSX) stock rating was shattered by Bernstein Research analysts on Tuesday to market-perform from their prior rating of outperform.

Analyst of the Bernstein Research kept their price target on the company stock at $6 per share.

Analyst further reported in a memo to investors that they believe that downside is limited at present valuation, but they are stepping to the sidelines as they do not observe further catalysts to the upside as they look out to 2013.

Boston Scientific Corp’s stock moved up 7 cents per share to settle at $5.66 on Monday.

Its competitors include Abbott Laboratories (NYSE:ABT) that slipped -0.33% to $64.16 with the total traded volume of 987,817.00 shares and Johnson & Johnson (NYSE:JNJ) that dropped -0.20% to $68.95 with the total traded volume of 1.75 million shares.

Other healthcare stocks with bullish trend include ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) up 147.83% to $5.71, Mylan Inc (NASDAQ:MYL) up 0.19% to $27.04 and Pfizer Inc.(NYSE:PFE) up -0.39% to $24.39, whereas with bearish trend include Merck & Co., Inc (NYSE:MRK) down -0.09% to $44.16, Bristol Myers Squibb Co (NYSE:BMY) down -0.31% to $32.63 and Sarepta Therapeutics Inc (NASDAQ:SRPT) down -4.35% to $29.66.

Boston Scientific Corporation (NYSE:BSX) stock in current session held volume of 9.19 million shares as compare to its average volume of 15.50 million shares. The stock after opening at $5.61 hit high price of $5.72and then trading at $5.68 by scoring ++0.35%.

As the revenue measures BSXgenerated revenue of 7.28billion in the following twelve months income of -$4022.00million. The Company showed a negative -55.27% in the net profit margin and in addition to in its operating margin which remained -52.41%. Company’s annual sales growth for the past five year was -0.51%.

The stock showed weekly upbeat performance of 10.12% which was maintained for the month at 10.98%. Likewise the positive performance for the quarter was recorded as 4.81% and for the year 6.59% while the YTD performance remained at 5.99%.

The BSX past twelve months price to sales ratio was 1.07 and price to cash ratio remained 22.08. As far as the returns are concern, the BSX return on equity was recorded as -43.84% and decreased -23.18% return on investment while its return on asset stayed at -20.95%.

DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with! CLICK HERE TO START YOUR FREE 30-DAY TRIAL

This entry was posted in Healthcare, Latest Headlines and tagged , , , , , , , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.